Researchers have identified 44 genetic regions associated with metabolite levels in the body, which can influence cardiovascular risk. The study found a potential molecular mechanism by which six genetic loci are linked to cardiovascular risk through the metabolites they regulate.
A team of researchers at the University of Toronto has developed a rapid screening system to identify compounds that can stop the growth of amyloid proteins. The study found 40 compounds that demonstrate the ability to inhibit amyloid formation, providing a promising lead for future disease treatments.
TYRA-300 shows promise in treating metastatic bladder cancer patients with FGFR3 gene mutations, achieving a 50% overall response rate and 100% disease control rate. The treatment also displays improved tolerability with lower side effects compared to existing pan-FGFR inhibitors.
Researchers have discovered key mutations in certain cancer cells that render WRN inhibitors ineffective. The study found that prolonged exposure to these inhibitors can lead to the acquisition of mutations in the WRN gene, allowing cancer cells to survive and develop resistance.
Researchers developed an in vitro model of murine peritoneal macrophage aging to study molecular mechanisms and develop innovative strategies. Chronic treatment with CB3 completely prevented the increase of p21CIP1 and maintained proliferative activity in day 14 macrophages.
Researchers have developed a 'mini-protein' that targets cancer cells expressing Nectin-4, allowing for direct delivery of radiation to tumours. The treatment shows promise in targeting multiple types of cancers and has the potential to be safe for repeated administrations.
Researchers at MedUni Vienna identified a potential way forward for targeted therapies that do not rely on antibiotics. The study focused on the restriction-modification system of Borrelia bacteria and discovered its importance in protecting the bacteria against foreign DNA.
Researchers at Nagoya University have identified a chemical compound that regulates stomatal density in plants, reducing water loss through transpiration. The compound, Stomidazolone, inhibits stomatal development without affecting plant growth, offering a promising solution for drought-prone environments.
A clinical trial suggests that tucatinib and trastuzumab may benefit patients with rare bile duct cancer who also have HER2-mutated breast cancer. The treatment combination showed a 46.7% objective response rate in patients with bile duct cancer, compared to 22.2% in the broader patient group.
Researchers developed an efficient analysis method to precisely determine gamma-glutamyl dipeptide concentrations, enabling prediction of full-bodied cheese flavor development. The method uses ultra-high performance liquid chromatography-mass spectrometry and can analyze 60 cheese samples per day.
A clinical study published in Clinical Cancer Research confirmed that tissue stiffening in HER2-negative breast cancer can directly cause disease progression and metastasis. The use of the MeCo Score diagnostic tool was found to predict the likelihood of relapse or recurrence among patients with early-stage breast cancer.
Researchers discovered a gene-mutation pathway that can lead to targeted therapies for blood cancers. The TET2 gene's enzymatic activity regulates chromatin state and leukaemogenesis, providing new therapeutic targets.
Researchers at Weill Cornell Medicine identified a unique enzyme called FTSJ1 that enables melanoma cells to escape oxidative stress and spread. By targeting this enzyme, therapies may prevent or treat metastasis with minimal side effects.
Researchers found that WNTinib significantly delayed tumour growth and extended survival in mice with hepatoblastoma cells harboring CTNNB1 mutations. The treatment also showed promise in shrinking tumors in patients' tumor tissue models, with some tumors disappearing completely.
Researchers humanize the lupus-derived autoantibody 3E10, preserving its therapeutic efficacy, to create novel cell-penetrating antibodies targeting tumors and RAD51. Humanized variants exhibit faster cell uptake and superior in vivo tumor targeting.
A new study found that fibroblast growth factor 21 (FGF21) is an independent predictor of all-cause mortality in older adults. The Polsenior2 study revealed that middle and high FGF21 levels were associated with increased mortality risk, particularly when adjusted for age, co-morbidities, and blood parameters.
Researchers at U of T have discovered that C2H2 zinc finger proteins, which primarily bind to DNA, also regulate RNA processing through various mechanisms. These proteins modify mRNA, controlling its length and altering it after transcription.
Researchers discovered a previously unknown class of compounds in the fungus Bipolaris victoriae S27 that effectively kill colorectal cancer cells. The most effective compound, bipoterpride No. 2, targets the DCTPP1 enzyme and shows promise as a potential new treatment option.
SourceWiley·JournalAngewandte Chemie International Edition·TypeExperimental study·DateOct 17, 2024
Researchers at Weill Cornell Medicine have discovered a biomarker that can predict which patients with liver cancer are likely to benefit from immunotherapy. The study found that high levels of the immune-suppressing protein NBR1 may identify patients who will not respond to treatment, while lowering NBR1 levels may help shrink tumors.
A recent study published in Nature Cancer has discovered that cancer cells exhibit opposing pro and antitumor programs, with the former promoting metastasis and the latter combating tumor growth. This finding opens new avenues for therapeutic strategies to target highly aggressive and therapy-resistant tumors.
Researchers at Weill Cornell Medicine have developed a virtual screening approach to identify small molecule drug candidates targeting cancer checkpoints. The method successfully identified two compounds with potential therapeutic activity against TIM-3 and VISTA inhibitory checkpoints.
Research highlights molecular chaperones' role in maintaining tumor suppressor stability and functional integrity. This understanding is crucial for developing targeted therapies for multiple cancers.
Researchers at EMBL Hamburg and CSSB have uncovered the molecular details of vitamin B1 absorption, revealing critical transporters and barriers that hinder its progress. The study sheds light on rare diseases caused by SLC19A3 mutations and potentially life-threatening hidden deficiencies triggered by certain medications.
Researchers at Japan Advanced Institute of Science and Technology have developed a novel method to culture antitumor bacteria using porous scaffolds, enhancing their anticancer properties and improving safety in animal testing. The approach resulted in improved survival rates in mice with breast cancer, including drug-resistant cases.
TP53 mutations are commonly associated with therapy-related AML and complex cytogenetics. Researchers found improved long-term outcomes when allo-HCT was performed during Complete Remission 1 (CR1), despite limited effective therapies for TP53-mutated AML.
A new magnetic gene therapy technology allows for precise control of specific brain circuits non-invasively with magnetic fields. The technology has shown promise in reducing abnormal movements in a mouse model of Parkinson's disease, and may have potential applications for treating psychiatric disorders and chronic pain.
Researchers at Baylor College of Medicine have discovered DAPK3 as a key regulator of TNBC cell migration. The study found that eliminating DAPK3 protein leads to prevention of migration and invasion in laboratory experiments. Further studies are needed to assess its potential value as a therapeutic target.
Researchers at Lehigh University are developing predictive models for gene editing with CRISPR to improve outcomes and expand medical applications. The team is using AI and advanced computer models to simulate the effects of altering a single gene on the entire genome, enabling them to predict and avoid unintended consequences.
Researchers used AI to repurpose FDA-approved drugs for chronic pain treatment. The LISA-CPI framework identified compounds that can bind to specific pain receptors and modulate signaling effects. Studies are underway to validate these compounds in the lab, offering a promising approach to advanced pain management.
Researchers at Michigan Medicine have discovered a new subtype of aggressive prostate cancer and identified a potential degrader to target it. The study found that a genetic alteration in the CDK12 gene drives cancer development, and a degrader targeting this gene shows promise in destroying cancer cells.
Researchers review UBA1 loss of function in VEXAS Syndrome, a hematoinflammatory disorder characterized by severe inflammation, cytopenias, and oncogenicity. They explore therapeutic options, including clone-targeting drugs, to combat this challenging disease.
Researchers at Houston Methodist are working on a national consortium to develop vaccines against two common and destructive strains of herpesviruses. The project aims to create prophylactic and therapeutic vaccines using a computational toolkit that could transform vaccine development.
A new non-invasive imaging technique has been shown to accurately detect clear-cell renal cell carcinoma, the most common form of kidney cancer. The technique uses a monoclonal antibody drug that targets the protein CA9, highly expressed in up to 95% of clear cell kidney cancers.
Scientists at RIKEN CPR created a method to change albumin's molecular ID card, allowing for targeted treatments against diseases like cancer. The new technology can transport proteins out of the body, mimicking drug delivery and removal.
A research team developed an RNA-based sensor platform that can regulate gene expression in bacteria, mimicking natural biological interactions. The START platform enables tunable control over sensor response and detection of various molecules, including drugs and proteins.
Researchers created the largest atlas of how tumor architecture changes in response to immune checkpoint therapy. The study found that multiple T cells recognize different neoantigens, altering the tumor ecosystem, and challenged prevailing theories on immunotherapy.
A new brain-mapping neurotechnology called Single Transcriptome Assisted Rabies Tracing (START) has been developed to map the brain's intricate neuronal connections. The technique combines two advanced technologies to resolve cortical connectivity at the resolution of transcriptomic cell types, enabling the identification of distinct p...
Researchers have identified key molecular targets that could significantly enhance the healing of both acute and chronic wounds. The study found that combinatorial therapy involving FGF7 and an MMP10-neutralising antibody can improve wound healing in both acute and chronic wounds.
Dr. Roger Lo has been awarded a $2 million NIH grant to investigate ways to prevent drug resistance in melanoma treatment and improve the effectiveness of MAPK inhibitors. The team aims to target genetic instability and immune evasion to stabilize the melanoma genome and make it more vulnerable to immune attacks.
A Virginia Tech research team has identified a molecular mechanism by which Shigella flexneri bacteria manipulate host molecules to ensure their survival. The study provides a new understanding of the infection pathway and its potential implications for preventing similar infections in other bacteria.
Researchers at Tel Aviv University discovered that aneuploid cells, which have an abnormal number of chromosomes, are more susceptible to certain types of anticancer drugs. The studies found that disrupting the MAPK pathway increases the sensitivity of these cancer cells to chemotherapy.
Researchers at UCSF have identified a molecular pathway that controls the formation of scar tissue in spinal cord injuries. By activating this pathway, they were able to reduce scarring and promote healing in mice with spinal cord injuries.
Researchers discover PG3 activates p21, PUMA, and DR5 in cancer cells through ATF4 and ISR, independent of p53. The study provides insights into a novel mechanism by which PG3 induces cell death.
A study published in mAbs reveals that up to one-third of antibody-based drugs exhibit nonspecific binding to unintended targets, a serious concern for patient safety. The Membrane Proteome Array technology helped identify this issue, challenging the long-held belief in absolute antibody specificity.
A new study in ACS Pharmacology & Translational Science investigates the molecular mechanisms behind Efavirenz's negative effects on brain function. The research reveals that the drug alters lipid metabolism and downregulates certain enzymes, which could lead to the development of new drugs to block its negative activity.
Researchers at UCSF used cryogenic electron microscopy to study the protein TGF-Beta, which plays a crucial role in development and cancer. They found that TGF-Beta can signal even when bound to a 'straitjacket' within the cell membrane, challenging decades-old dogma on its function.
Researchers developed SINGULAR, a cell rejuvenation atlas that offers a comprehensive systems biology analysis of diverse rejuvenation strategies across multiple organs at single-cell resolution. The study identified master regulators and uncovered common targets across immune cells.
CAR-T cell therapy, a regenerative immunotherapy, has shown promise in treating blood cancers but struggles with T-cell exhaustion. Researchers have discovered that overproduction of the IL-4 protein causes this exhaustion and used CRISPR gene-editing technology to remove it, improving CAR-T cell therapy outcomes.
Researchers used a dual blockade of IL-10 and PD-1 to control SIV viral rebound after treatment interruption. The approach led to significant reduction in viral loads and reservoirs, showing promise for HIV treatment strategies.
Proteolysis targeting chimeras targeting peroxisome proliferator-activated receptors (PPARs) show promise in overcoming challenges of PPAR-targeted therapies. They offer enhanced tumor specificity due to differential E3 ligase expression, reducing off-target effects and improving therapeutic outcomes.
Researchers discovered a key molecule, PAF, that controls the destiny of immune cells and turns them against cancer. The study highlights the importance of targeting PAF to develop new therapies for various types of cancer.
A new study published in The FEBS Journal found that protein C1QL1 plays a crucial role in promoting the replacement of specialized cells responsible for producing myelin. This discovery could lead to novel therapies for demyelinating diseases like multiple sclerosis.
Newly developed tools enable selective labeling and manipulation of synapses, advancing understanding of learning, memory, and neurological disorders. The review highlights promising molecular actuators and optogenetic approaches to unravel synaptic function mysteries.
Researchers at UCSF develop a method to target GTPases, enzymes involved in Parkinson's and many other diseases, by using drugs targeting the K-Ras oncogene. This approach reveals new drug binding sites that could not be predicted by computational tools.
A new study published in Microorganisms highlights the importance of small molecule drugs that target the unchanging parts of the SARS-CoV-2 virus. The research suggests that these stable targets could provide a consistent and reliable treatment option for COVID-19, even as vaccines are updated to address changing viral strains.
Researchers have found a potential compound that pairs well with an IRAK4 inhibitor to kill AML cells by reducing c-Myc levels, a protein also driving cancer growth. The three-year LLS grant will allow further research into the effects of IRAK4 targeting on c-Myc.
Researchers developed a novel strategy for designing MOFs, merging bottom-up and top-down approaches to explore structures based on metal clusters. The Up-Down Approach enables the creation of novel materials with tailored properties, including high chemical stability and diverse chemical properties.
A novel synthetic biology platform enables rapid and cost-effective transformation of protein binders into high-contrast nanosensors for various applications. The platform uses fluorogenic amino acids to increase fluorescence up to 100-fold, enabling the detection of specific proteins, peptides, and small molecules.
Researchers have discovered a stable intermediate form of the serotonin-gated 5-HT3A receptor, which could serve as a new drug target for psychiatric and gastrointestinal disorders. The study provides insights into the synthesis and assembly of membrane proteins.
Researchers analyzed young and aged dermal fibroblasts, finding a significant decrease in protein secretion with age. The study also revealed an increase of over 60% in cytoplasmic protein accumulation, highlighting the cytoskeleton's crucial role in skin aging.